CXCL14是TLR9激动剂诱导的抗瘤免疫反应的重要调节剂
Kosuke Tanegashima1, Eiji Esashi2, Koji Ishida2
1Stem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
Journal of immunology (Baltimore, Md. : 1950)
|May 22, 2025
概括
一种新的CpG寡氧核酸 (ODN),A602,通过与CXCL14一起工作来增强抗瘤免疫力. 这种组合疗法在小鼠模型中显示出强大的抗癌作用,突出了癌症免疫治疗的新方法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- CpG oligodeoxynucleotides (ODNs) 是托尔类受体9 (TLR9) 的激动剂,也是炎症性细胞因子和I型干扰素的强有力的诱导剂.
- 临床试验表明,需要更有效的人类TLR9主激素CpGODN用于癌症免疫治疗.
研究的目的:
- 开发一种强大的CpG ODN (A602),可诱导抗瘤免疫反应.
- 调查CXCL14在增强CpG ODN A602.2.的疗效中的作用.
主要方法:
- 开发了A602,并对其诱导干扰素α的能力在人类外周血液单核细胞中进行了测试.
- 在各种免疫细胞系中评估了CXCL14对A602和TLR9介导免疫反应的细胞吸收的影响.
- 单独和与CXCL14结合的A602的抗瘤活性在结直肠癌,B型淋巴瘤和黑色素瘤的同源性小鼠模型中进行了评估.
- 使用CXCL14淘汰赛小鼠确定了内源CXCL14的必要性.
主要成果:
- A602诱导人体外周血液单核细胞的干扰素α分泌.
- CXCL14增强了免疫细胞中A602的细胞吸收,促进了TLR9介导的反应.
- 在小鼠模型中,A602对CT26,A20和B16F10癌细胞表现出显著的抗瘤活性.
- 在CXCL14淘汰赛小鼠中,A602对B16F10黑色素瘤的抗瘤作用被废除,证实了内源CXCL14的需求.
结论:
- 新型CpG ODN A602,与CXCL14结合,有效诱导抗瘤免疫反应.
- 内源性CXCL14对于由A602.2调解的瘤抑制作用至关重要.
- 调节CXCL14为开发新的抗瘤免疫疗法提供了一个有希望的创新策略.
相关概念视频
T Cell Activation and Clonal Selection
6.0K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
6.0K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Tumor Immunotherapy
677
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677


